KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Other Operating Expenses (2016 - 2025)

Historic Other Operating Expenses for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Q3 2025 value amounting to $43.3 million.

  • Supernus Pharmaceuticals' Other Operating Expenses rose 2006.66% to $43.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $168.8 million, marking a year-over-year increase of 186.24%. This contributed to the annual value of $149.8 million for FY2024, which is 1896.98% down from last year.
  • Supernus Pharmaceuticals' Other Operating Expenses amounted to $43.3 million in Q3 2025, which was up 2006.66% from $37.6 million recorded in Q2 2025.
  • Supernus Pharmaceuticals' Other Operating Expenses' 5-year high stood at $60.7 million during Q4 2023, with a 5-year trough of $22.0 million in Q1 2021.
  • Its 5-year average for Other Operating Expenses is $38.2 million, with a median of $40.4 million in 2023.
  • In the last 5 years, Supernus Pharmaceuticals' Other Operating Expenses soared by 30607.8% in 2021 and then crashed by 2633.94% in 2024.
  • Supernus Pharmaceuticals' Other Operating Expenses (Quarter) stood at $30.1 million in 2021, then soared by 36.86% to $41.2 million in 2022, then soared by 47.11% to $60.7 million in 2023, then dropped by 26.34% to $44.7 million in 2024, then decreased by 3.15% to $43.3 million in 2025.
  • Its Other Operating Expenses stands at $43.3 million for Q3 2025, versus $37.6 million for Q2 2025 and $43.2 million for Q1 2025.